PCRI’s Executive Director, Mark Scholz, MD, discusses a range of solutions for alleviating fatigue brought on by androgen deprivation therapy (also known as testosterone inactivating pharmaceuticals or TIP).
0:10 Fatigue is the most common side effect experienced by men undergoing androgen deprivation therapy, and it is most often the result of reduced muscle mass caused by the lack of testosterone.
0:44 The best way to counteract fatigue from treatment is to have a consistent devotion to exercising, specifically weightlifting, 2-3 times per week. Significant muscle mass loss can occur in as little as two weeks, so any lapse in your weightlifting regimen can have serious negative consequences including reintensifying fatigue. Typically, consistent and diligent weightlifting will reduce the amount of fatigue that men experience by about 80%.
2:07 There are other possible causes for fatigue while taking androgen deprivation therapy (e.g. Low thyroid levels, low B12 levels), and so it is important that your doctor is checking for these rather than assuming that the source of fatigue must be from the lack of testosterone.
2:30 On rare occasions the absence of testosterone may cause anemia to occur. If anemia becomes severe then cardiorespiratory reserve is reduced and shortness of breath with minimal exercise will occur. Most cases are mild and do not require treatment, however, if it becomes severe (usually signaled by hemoglobin less than 10 or a hematocrit under 30%) then pharmaceutical agents like Aranesp or Procrit can restore blood levels to an acceptable range. Transfusions have greater risks and should not be considered unless the situation is horribly severe.
3:31 Other solutions for treatment-related fatigue include the use of caffeine or Provigil (modenafil), a stimulant-like medicine typically used to treat narcolepsy. These are most effective when they are used occasionally so that your body will become acclimatized to their absence and their effectiveness will be reestablished.
4:15 Another thing to consider is the pharmaceutical agent(s) that are being used for the androgen deprivation therapy and the duration of treatment. A shorter duration of treatment might be appropriate for elderly men with milder forms of cancer who are experiencing extreme fatigue. Xtandi is more associated with fatigue than its most similar competitor Zytiga, so it is worth considering switching if Xtandi is causing fatigue. Casodex is an oral agent that has less potent anti-cancer efficacy than injectibles like Lupron, but it also causes significantly fewer side effects. In elderly patients or patients with severe fatigue, Casodex is worth considering as a substitute for the stronger injectible agents.
Don’t know your stage? Take the quiz: Visit www.prostatecancerstaging.org
To learn more about prostate cancer visit www.pcri.org
To download the free Staging Guide visit www.pcri.org/prostate-cancer-s...
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's RU-vid channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD
30 июл 2024
